RELMADA THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
RELMADA THERAPEUTICS, INC. (RLMD) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $7.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $6.28M.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$2.71M.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$2.76M, a 111.73% decline year-over-year.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $23.50M, a 4686.45% increase year-over-year.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$360.49K.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$234.54K.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$1.30M.
- RELMADA THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$39.05M, a 193.09% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.84M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.28M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$360.49K 10-K · filed 2026-03-19 | |||
| 2025-09-30 | -$2.47M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$2.50M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$2.71M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$234.54K 10-K · filed 2026-03-19 | |||
| 2024-09-30 | -$2.61M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$2.01M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$2.76M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$1.30M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $1.30M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $9.07M 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $23.50M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$39.05M 10-K · filed 2024-03-19 | |||
| 2022-09-30 | -$1.92M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | -$7.18M 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $490.94K 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $41.95M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $8.95M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $2.17M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $1.31M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$33.78M 10-K · filed 2022-03-25 | |||
| 2020-09-30 | -$28.73M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$22.45M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | -$24.05M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $27.06M 10-K · filed 2021-03-24 | $33.85M 10-K · filed 2021-03-24 | ||
| 2019-09-30 | $5.42M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $6.79M 10-Q · filed 2020-08-12 | $6.98M 10-K · filed 2021-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |